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Abstract
It has been suggested that A3 adenosine receptors (ARs) play a role in the pathophysiology of cerebral ischemia with dual and opposite
neuroprotective and neurodegenerative effects. This could be due to a receptor regulation mediated by rapid phosphorylation and
desensitization carried out by intracellular kinases. In this study, we investigated the involvement of extracellular regulated kinase (ERK 1
and 2), members of the mitogen-activated protein kinase (MAPK) family, in A3 AR phosphorylation. A3 AR mediated the activation of ERK
1/2 with a typical transient monophasic kinetics (5 min). The activation was not affected by hypertonic sucrose cell pre-treatment, suggesting
that this effect occurred independently of receptor internalization. The involvement of MAPK cascade in the A3 AR regulation process was
evaluated using two well-characterized MAPK kinase inhibitors, PD98059 (2-(2V-amino-3V-methoxyphenyl)oxanaphthalen-4-one) and U0126
(1,4-diamino-2,3-dicyano-1,4-bis (aminophenylthio) butadiene). The exposure of cells to PD98059 prevented MAPK activation and inhibited
homologous A3 AR desensitization and internalization, impairing agonist-mediated receptor phosphorylation. PD98059 inhibited the
membrane translocation of G protein-coupled receptor kinase (GRK2), which is involved in A3 AR homologous phosphorylation, suggesting
this kinase as a target for the MAPK cascade. On the contrary, the chemically unrelated inhibitor of the MAPK cascade, U0126, did not
significantly affect GRK2 membrane translocation or receptor internalization. Nevertheless, the inhibitor induced a significant impairment of
receptor phosphorylation and desensitization. These results suggested that the MAPK cascade is involved in A3 AR regulation by a feedback
mechanism which controls GRK2 activity and probably involves a direct receptor phosphorylation.
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1. Introduction
Adenosine accumulates in high concentrations in the ex-
tracellular regions of various synapses during pathophysio-
logical conditions such as trauma, hypoxia and shock [1–3].
Even though there are some adverse side effects associated
with adenosine production, during cerebral ischemia, there
is still clear evidence that the nucleoside is an endogenous
neuroprotectant [4]. The major disadvantage appears to be
the overproduction of adenosine for extended periods of
time, thereby gradually reducing its efficacy. This effect
might be related to adaptive changes of brain adenosine re-
ceptors (AR) [5–8], i.e. homologous and heterologous de-
sensitization processes, common mechanisms involved in
the regulation of the G protein-coupled receptor (GPCR)
function [9].
The signalling capacity of GPCRs can be modulated by
receptor phosphorylation, which in turn stimulates the bind-
ing of arrestin proteins [10,11]. This event serves at least
two functions: (1) uncoupling from G proteins, thereby
leading to a functional desensitization of G protein linked
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signalling; (2) clustering of phosphorylated receptors into
clathrin-coated pits. Moreover, the GPCRs activation in-
duced the recruitment of Src family tyrosine kinases, which
ultimately results in the activation of the mitogen-activated
protein kinase (MAPK) signalling cascade [12,13]. Intrigu-
ing evidence demonstrated that MAPK, besides converging
mitogenic signals to the nucleus, represents a feedback sig-
nal, originating at the effector pathway itself, involved in
GPCR regulation mechanisms [14]. What then the potential
targets are for this desensitizing signal emanating from the
MAPK cascade is not yet known. One possibility is the
direct receptor phosphorylation by MAPK as described for
angiotensin II receptors [15]. Another possibility is the
direct or indirect interaction between the MAPK cascade
and G protein-coupled receptor kinase (GRK2) proteins
[16,17], which are involved in GPCR phosphorylation.
Although the activation of the MAPK pathway by A1,
A2A and A2B and A3 ARs has been demonstrated [18–22],
no data are available so far about the involvement of this
intracellular phosphorylative cascade in ARs regulation.
We have recently demonstrated that human A3 AR undergo
a rapid desensitization and internalization [23]. In this con-
text, we set out to investigate the role of activated MAPK
on the A3 AR regulation mechanism. We demonstrated
that A3 AR-mediated MAPK activation occurs in a man-
ner independent from receptor internalization. Moreover,
we show that MAPKs are involved in A3 AR regulation,
both contributing to direct receptor phosphorylation and
controlling GRK2 membrane translocation. These results
suggest a new autoregulatory loop in the A3 AR-MAPK
signalling pathway.
2. Materials and methods
[125I] AB-MECA, a-[32P]ATP and [32P] orthophosphate
were from NEN Life Sci, (Ko¨ln, Germany). Sodium deoxy-
cholate, Nonidet P-40, SDS, phenylsulfonylfluoride (PMSF),
aprotinin and orthovanadate, PD98059, U0126, Ro 201724
and adenosine deaminase (ADA) were from Sigma. All elec-
trophoresis reagents were from Bio-Rad. Cell culture media
and fetal calf serum were from Bio-Whittaker (Walkersille,
USA) and Boehringer/Roche (Basel, Switzerland), respec-
tively. Mouse monoclonal phosphospecific antibody against
ERK 1/2, rabbit polyclonal antibody against GRK2 and hor-
seradish peroxidase (HRP) conjugated secondary antibody
were from Santa Cruz Biotechnology (Germany). Human A3
AR antibody were supplied by Alpha Diagnostic (San Anto-
nio, USA). Protein-A Sepharose was from Amersham Phar-
macia Biotech (Italy). All other chemicals were supplied by
standard commercial sources.
2.1. Cell culture
Chinese hamster ovary (CHO) cells, stably transfected
with human A3 AR [24], were grown adherently and main-
tained in Dulbecco’s Modified Eagle Medium with a nu-
trient mixture F12 (DMEM/F12) without nucleosides,
containing 10% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 Ag/ml), L-glutamine (2 mM) and genet-
icin (0.2 mg/ml) at 37 jC in 5%CO2/95% air, essentially as
previously described [24]. Cells were split two or three
times weekly at a ratio between 1:5 and 1:20 and used for
immunoblotting, adenylyl cyclase activity and internaliza-
tion experiments at subconfluency. The cells had a viability
> 95%, as assessed by the exclusion of trypan blue.
2.2. MAPK phosphorylation and immunoblotting
Treatment of the cells was carried out with NECA (10
AM) for different time intervals (1 min–2 h) at 37 jC in
serum-starving medium. When indicated, ERK 1/2 phos-
phorylation was evaluated in the presence of the antagonist
XAC (1 AM) or sucrose (0.45 M) to block receptor internal-
ization. All the experiments were performed in the presence
of 2 U/ml ADA.
Following incubation, monolayers were directly lysed in
500 Al/well RIPA buffer (150 mM NaCl, 50 mM Tris–HCl,
pH 8, 1% Nonidet P-40, 0.5% sodium-deoxhyxolate, 1 mM
PMSF, 10 Ag/ml aprotinin, 100 AM NaVO4) for 60 min at 4
jC. After centrifugation at 15,000 g for 30 min, soluble
fractions were assayed for protein content using the BioRad
(Richmond, CA) protein assay with bovine serum albumin
as the standard.
For immunoblotting, equivalent amounts of protein (typ-
ically 30 Ag/sample) were resolved by SDS-PAGE using
10% (w/v) polyacrylamide resolving gels. The appropriate
amounts of cell lysate were prepared for electrophoresis by
boiling for 5 min before loading for SDS-PAGE. Resolved
proteins were transferred to nitrocellulose and the mouse
phosphospecific ERK 1/2 IgG was used for immunoblotting
(1:500) for 2 h at room temperature. After extensive wash-
ing with TBS (10 mM Tris–HCl, 150 mM NaCl, pH 8)
containing 0.05% Tween-20, the nitrocellulose membrane
was incubated for 2 h at room temperature with HRP goat
anti-mouse conjugated secondary antibody, diluted to
1:15,000 in Blotto A (TBS, 0.05% Tween-20, 5% low-fat
dried milk). The series of washes described above were then
repeated and followed by two additional washes in TBS
before visualization of reactive proteins by an enhanced
chemiluminescence protocol ECL (Amersham Pharmacia
Biotech). Immunoblotting was quantified by densitometric
scanning of films exposed in the linear range.
2.3. A3 AR phosphorylation
CHO cells were plated onto 6-well dishes at a density of
approximately 1106 cells/well and cultured overnight in
regular medium. The next day, the cells were washed three
times with PBS buffer and labelled with 0.2 mCi/ml [32P]
orthophosphate for 90 min. Either PD98059 (50 AM) or
U0126 (1 AM) was then added, and incubation was con-
M.L. Trincavelli et al. / Biochimica et Biophysica Acta 1591 (2002) 55–6256
tinued for another 90 min or 15 min, respectively. Labelled
cells were exposed to NECA (10 AM) for 5 min, in the
absence or in the presence of the inhibitors. After incuba-
tion, cells were placed on ice and washed three times with
ice-cold PBS. Cells were solubilized by the addition of 300
Al RIPA buffer and incubation for 60 min on a rotating
wheel. Extracts were then equalized by protein assay and
incubated with rabbit anti A3 AR antibody for 2 h at 4 jC.
Receptors were then immunoprecipitated from supernatants
by incubation for 2 h with protein A-Sepharose in the
presence of 0.3% BSA. Immune complexes were isolated
by centrifugation, washed three times with washing buffer
(150 mM NaCl, 10 mM Tris, 1% NP-40, pH 7.8), and eluted
from protein A-Sepharose by the addition of electrophoresis
sample buffer and incubation at 37 jC for 1 h. Analysis was
by SDS-PAGE electrophoresis using 10% (w/v) polyacry-
lamide resolving gels and autoradiography.
2.4. Determination of receptor desensitization by
measurement of adenylyl cyclase activity
Desensitization was carried out by incubating the cells
with the agonist NECA (10 AM) for different times (1–30
min) at 37 jC. Following desensitization, the medium was
removed and the cell monolayer was given three 5-ml rapid
washes with warm culture medium. Then, membranes were
prepared and immediately tested for adenylyl cyclase activ-
ity. Adenylyl cyclase assays were performed using the phos-
phodiesterase inhibitor Ro201724 (20 AM), as previously
described [23]. Functional desensitization of human A3 AR
was determined by evaluating the ability of 1 AM IB-MECA
to inhibit the forskolin-stimulated adenylyl cyclase activity.
Desensitization studies were also performed following treat-
ment of the cells with the MAPKK inhibitors PD98059 (50
AM) or U0126 (1 AM).
2.5. Internalization binding assay
Internalization studies were carried out as previously
described [23]. When indicated, cells were preincubated
with PD98059 (50 AM) for 60 min or U0126 (1 AM) for 15
min and the inhibitors were included during internalization
experiments.
2.6. GRK2 translocation
CHO cells were treated with NECA (10 AM) for 5 min,
washed thoroughly in PBS buffer and rapidly lysed in a
hypotonic solution containing 10 mM Tris, pH 7.4, 5 mM
EDTA, 2 Ag/ml pepstatin, 5 Ag/ml benzamidine and 5 Ag/ml
soybean trypsin inhibitor. Membrane and cytosolic fraction
were prepared by centrifugation at 40,000 g for 15 min.
Equal amount of cytosolic and particulate fraction proteins
were resolved by SDS-PAGE electrophoresis and GRK2
translocation was evaluated by immunoblotting using a
polyclonal antibody. GRK2 membrane translocation was
also evaluated following treatment of the cells with the
MAPKK inhibitor PD98059 (50 AM) or U1026 (1 AM).
2.7. Data analysis
We used the GS-670 BIO-RAD imaging densitometer for
quantitative analysis of the immunoblots. For data analysis
and graphic presentation, we used the non-linear multi-
purpose curve-fitting computer program Graph-Pad Prism
(GraphPad, San Diego, CA).
3. Results
3.1. Rapid ERK 1/2 activation by A3 AR agonist
To examine the time course of ERK 1/2 activation in
response to A3 AR stimulation, stably transfected CHO cells
were exposed to 10 AM NECA at 37 jC for different times
(1–120 min). The use of the non-specific agonist NECA
was possible due to the lack of co-expression of the other
adenosine receptor subtypes in CHO transfected cells.
Immunoblotting with an antibody against phosphotyrosine
revealed an increased immunostaining of bands migrating at
42 and 44 kDa in the presence of NECA. As shown in Fig.
1, 10 AM NECA induced a sharp time-dependent rise in
phospho MAPK-like immunoreactivity. After stimulation of
the cells with micromolar NECA concentration, ERK 1/2
phosphorylation reached a maximal value (11.2F 0.9-fold
vs. control) at 3–5 min. After 30 min NECA stimulation,
the levels of phosphorylated ERK 1/2 were still almost 4-
fold higher than control levels, whereas after 2 h, they
returned to control levels.
Fig. 1. Time course of ERK 1/2 phosphorylation in CHO cells after agonist
stimulation. CHO cells were incubated with 10 AM NECA for 1–120 min
as indicated. Then, the cells were lysed, and the extent of ERK 1/2 phos-
phorylation was determined by immunoblotting with an antiserum recog-
nizing the dually phosphorylated p42 and p44 MAP kinase, as described in
Materials and methods. The immunoreactivity was quantified by densito-
metric scanning from both bands; data were normalized by setting the
control values to 1. Data are meansF SEM from three determinations.
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The ability of 1 AM XAC to prevent the NECA-mediated
activation of ERK 1/2 phosphorylation was also evaluated.
The results obtained showed that antagonist preincubation
of the cells completely prevented the NECA-induced
increase in ERK 1/2 phosphorylation (Table 1), suggesting
a specific A3 AR-mediated effect.
3.2. Inhibition of A3 AR internalization on rapid ERK 1/2
activation
It is known that A3 AR, following agonist activation,
internalizes with a rapid kinetics that peaks within 60 min
and this intracellular redistribution is blocked (about 70%)
by the presence of hypertonic sucrose as an inhibitor of
clathrin-mediated endocytosis [23]. To investigate the role
of receptor endocytosis in the activation of an intracellular
phosphorylation cascade, we evaluated the ability of 10 AM
NECA to modulate ERK 1/2 phosphorylation following
blocking of receptor endocytosis by 0.45 M sucrose. In this
experiment, we evaluated ERK 1/2 activation following 10
min agonist stimulation, a sufficient time to allow receptors
to internalize. The obtained results showed that in the
presence of sucrose, an even more pronounced ERK 1/2
activation was detectable (Table 1). These results demon-
strated that redistribution of the A3 AR from plasma mem-
brane into the endosomal compartment was not required for
MAPK activation. In all Western blot experiments, the
immunolabelling of total ERK 1/2 gave similar results en-
suring the same amount of proteins applied in each experi-
ment (data not shown).
3.3. Effects of inhibition of the MAPK cascade on
agonist-induced A3 AR phosphorylation
As phosphorylation of threonine residues within intra-
cellular A3 AR domains is an early step during receptor
desensitization [25] and internalization [26], we explored
the effects of two chemically unrelated MAPKK inhibitors,
PD98059 [27] and U0126 [28], on agonist-induced phos-
phorylation of A3 AR.
Treatment of the cells with 50 AM PD98059 or 1 AM
U0126, before and during NECA exposure, markedly
inhibited ERK 1/2 activation, compared with cells treated
with 0.1% DMSO as controls (Fig. 2).
When lysates from transfected CHO cells were immu-
noprecipitated and subjected to Western blot analysis, the
anti-A3 AR antibody detected a band migrating at a molec-
ular mass corresponding to 36–40 kDa (data not shown). To
determine receptor phosphorylation, we immunoprecipitated
receptor proteins from agonist-stimulated cells that had been
metabolically labelled with 32P. As shown in Fig. 3, 1–5
min cell treatment with 10 AM NECA stimulated phosphor-
ylation of A3 AR to 212.5F 17.5% and 310F 30% (vs.
control = 100%), respectively. Next, we determined agonist-
induced phosphorylation of A3 AR in the presence of the
MAPKK inhibitors, PD98059 or U0126. PD98059 (50 AM)
completely blocked agonist-induced phosphorylation
(110F 10%; P= 0.03 vs. NECA treated cells), without sig-
nificant changes in the basal phosphorylation levels. U0126
(1 AM) showed a significant decrease in receptor phosphor-
ylation (165F 15%;P= 0.049 vs.NECA treated cells).More-
over, a significant difference was observed between the A3
AR phosphorylation blocking induced by two inhibitors
(P= 0.025 PD98059 plus NECA vs. U0126 plus NECA).
3.4. Effects of inhibition of the MAPK cascade on
agonist-induced A3 AR desensitization
Next, we examined the effects of MAPKK inhibitors,
PD98059 and U0126 on human A3 AR desensitization. The
ability of IB-MECA to inhibit forskolin-stimulated adenylyl
cyclase activity was evaluated following incubation of the
Table 1
Effect of A3 AR antagonist and receptor internalization blocking on MAP
kinase phosphorylation
(a–d) Cells were incubated for 5 min with serum-free medium (control),
with 10 AM NECA, 1 AM XAC or a combination of agonist and antagonist.
(e–g) Cells were treated with serum-free medium containing 0.45 M
sucrose (control) for 30 min at 37 jC. Then, cells were incubated for a
further 10 min in the presence of 10 AMNECA in the continuing absence or
presence of internalization inhibitor. Following incubation, cells were lysed
and the extent of ERK 1/2 phosphorylation was determined by
immunoblotting with an antiserum recognizing the dually phosphorylated
p42 and p44 MAP kinase. The immunoreactivity was quantified by
densitometric scanning from both bands; data were normalized by setting
the control values to 1. Data are meansF SEM from three determinations.
Fig. 2. Inhibition of agonist-stimulated ERK 1/2 phosphorylation by
PD98059 and U0126. CHO cells were incubated with the agonist NECA
(10 AM) in the absence or presence of MAPK inhibitors PD98059 (50 AM)
or U0126 (1 AM) for 10 min. Following incubation, cells were lysed and
the extent of ERK 1/2 phosphorylation was determined by immunoblotting
with an antiserum recognizing the dually phosphorylated p42 and p44
MAP kinase.
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cells, for different times at 37 jC, with 10 AM NECA in the
absence and in the presence of 50 AM PD98059 or 1 AM
U0126. As shown in Fig. 4, the incubation of the cells with
NECA for 30 min reduced receptor responsiveness to
5F 0.4% compared with control cells (A3 AR desensitiza-
tion). The NECA-induced A3 AR desensitization kinetics
was rapid with a t1/2 of 3.23F 0.22 min
 1. The presence of
MAPKK inhibitors, before and during cell agonist treat-
ment, affected the A3 AR desensitization process. In partic-
ular, preincubation of cells with PD98059 retained receptor
responsiveness to 80F 6.4% vs. control cells, completely
preventing receptor desensitization; preincubation of the
cells with U0126, induced a significant (P < 0.0001) slow-
down of desensitization kinetics, which occurred with a t1/2
of 9.99F 0.41 min  1. In control cells, PD98059 and U0126
alone did not affect the ability of IB-MECA to inhibit
adenylyl cyclase activity. These results suggested that the
two tested MAPKK inhibitors affected receptor responsive-
ness by means of two different pathways.
3.5. Effects of inhibition of the MAPK cascade on
agonist-induced A3 AR internalization
We also examined the effects of PD98059 and U0126 on
A3 AR internalization. Treatment of the cells with 50 AM
PD98059 or 1 AM U0126 did not induce a significant
decrease in total cell-associated radioactivity, indicating that
these inhibitors had no effect on receptor binding properties.
When the cells were exposed to 50 AM PD98059 before and
during cell incubation with 10 AM agonist, internalization of
the ligand [125I] AB-MECA was markedly inhibited. Fol-
lowing 90 min of cell agonist treatment at 37 jC in the
presence of PD98059, the percentage of internalized ligand
was only 6% compared with 73% in control cells (Fig. 5).
Fig. 4. Inhibition of NECA-induced desensitization of A3 AR by PD98059
and U0126. CHO cells were preincubated with 0.1% DMSO (controls) or
50 AM PD98059 for 60 min or 1 AM U0126 for 15 min at 37 jC, and then
10 AM NECAwas added in the absence or in the presence of each inhibitor
for different times (1–30 min). Then, at each time point, cell monolayers
were washed to remove the agonist and membranes were prepared for
adenylyl cyclase activity. Desensitization of A3 AR responsiveness was
evaluated as the ability of the agonist IB-MECA (1 AM) to inhibit forskolin-
stimulated (6–8-fold) adenylyl cyclase activity compared with untreated
control cells (100%): inhibition of adenylyl cyclase activity by IB-MECA
in cells treated with 10 AM NECA (n), or 10 AM NECA in the presence of
PD98059 (E), or 10 AM NECA in the presence of U0126 (z). Data are
meansF SEM of 1 AM IB-MECA inhibition of adenylyl cyclase activity,
obtained from three separate experiments.
Fig. 5. Modulation of agonist-induced A3 AR internalization by PD98059
and U0126. Cells were preincubated in serum-free medium with 0.1%
DMSO (control; n), or 50 AM PD98059 (E) for 60 min at 37 jC, or 1 AM
U0126 (z) for 15 min, and then incubated with 1 nM [125I] AB-MECA at
37 jC for different times in the absence or presence of the MAPKK
inhibitors. The internalized radioactivity was evaluated at each time follow-
ing acid washing of the cells, and is expressed as a percentage of the total
cell-associated radioactivity (surface-bound plus intracellular radioactivity).
The values represent the meansF SEM of three different experiments.
Fig. 3. Inhibition of agonist-promoted phosphorylation of A3 AR by
PD98059 and U0126. CHO transfected cells labelled with 32P were
stimulated with 10 AM NECA for 1–5 min in the presence or absence of 50
AM PD98059 or 1 AM U0126. Cells were lysed, immunoprecipitated with
an anti A3 AR antibody and immunoprecipitates were resolved on 10%
SDS-PAGE. Gels were dried and subjected to autoradiography. (A) Phos-
phorylated A3 AR migrates as a band with a molecular mass of 36–40 kDa.
(B) Quantitative analysis of bands expressed as meansF SEM of three
separate experiments. Phosphorylation is expressed relative to that observed
in the absence of agonist (set to 100%).
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The treatment of the cells with the MAPKK inhibitor,
U0126, did not significantly affect A3 receptor internal-
ization. These results demonstrated an important role of the
intracellular kinase cascade in the regulation of A3 AR
intracellular trafficking.
3.6. Effects of inhibition of the MAPK cascade on GRK2
protein membrane translocation
In order to evaluate the involvement of GRK2 in MAPK-
mediated phosphorylation of A3 AR, we assessed the
plasma membrane GRK2 translocation following cell incu-
bation with 10 AM NECA in the presence or absence of the
MAPKK inhibitors. As shown in Fig. 6, cell treatment with
10 AM NECA at 37 jC for 5 min induced a significant,
sharp increase in membrane-associated GRK2. The preincu-
bation of the cells with PD98059, before and during agonist
treatment, completely prevented GRK membrane transloca-
tion (P= 0.014 vs. NECA treated cells). In contrast, cell
preincubation with U0126 did not significantly affect ago-
nist-mediated GRK2 membrane translocation (P>0.05 vs.
NECA treated cells). Cell treatment with the MAPKK
inhibitors, alone, did not significantly affect GRK2 subcel-
lular distribution.
4. Discussion
Repeated ischemic episodes cause adenosine liberation
up to concentrations (40 AM) [29] sufficient for the optimal
stimulation of A3 AR. As activation of the latter attenuates
the efficacy of presynaptic inhibition mediated by A1 AR
[30], A3 AR activation increased glutamate release and
NMDA receptor stimulation and potentiated adenosine
release. It is very likely that ischemia transforms the process
of adenosine-mediated ergotropic inhibition, which, under
physiological conditions, ensures the flexibility of synaptic
responses [31], into a self-sustaining process of ergotropic
excitation leading to neuronal death. Eventual loss of AR
either due to their desensitization or down-regulation will
finally interrupt the process. In this context, understanding
the mechanisms regulating receptor function, such as desen-
sitization and endocytosis, represents an important goal to
shed light on the role of these receptors in neuronal survival.
Many of the cellular responses mediated by GPCRs are the
result of the functional integration of an intricate network of
intracellular signalling pathways that ultimately converge on
MAPK cascade activation. Although it has recently been
established that activation of human A3 AR stimulates a
rapid, transient increase in MAPK activity [21], nothing is
known about the involvement of the MAPK pathway in
homologous desensitization and internalization of these
receptors. In the present work, we confirmed that in CHO
cells stably transfected with human A3 AR, the agonist-
mediated stimulation of A3 AR induced the activation of the
MAPK, ERK 1/2. We first demonstrated that the A3 AR did
not require internalization to evoke ERK 1/2 activation.
Interestingly, in the present study, we demonstrated that
ERK 1/2 activation plays an important role in the regulation
of A3 AR affecting receptor phosphorylation, desensitiza-
tion and internalization.
Exposure of CHO cells to micromolar NECA concen-
trations stimulated a rapid, transient activation of the MAPK
pathway with a maximum peak of ERK 1/2 phosphorylation
within 5 min. This phosphorylation disappeared slowly,
with an approximate half-life of 20 min. The rapid decline
in MAPK activity, despite continuous agonist presence,
could be due to short-term receptor desensitization. NECA-
induced ERK 1/2 activation was completely prevented by
preincubation of cells with the antagonist XAC. These re-
sults demonstrated that this effect was specifically mediated
by A3 AR activation, since this receptor subtype is the only
one expressed in CHO A3 cells [25]. Moreover, studies car-
ried out by Schulte and Fredholm [21] demonstrated that AR
ligands had no effects on ERK 1/2 phosphorylation in un-
transfected control cells.
Fig. 6. GRK2 membrane translocation. Cells were preincubated at 37 jC in
serum-free medium, or 50 AM PD98059 for 60 min, or 1 AM U0126 for 15
min, and then incubated with 10 AM NECA for 5 min. Membrane and
cytosolic fraction were separated, as described in Materials and methods,
and GRK2 was immunolabelled by electroblotting, using a specific
polyclonal antibody. The immunoblots are representative of an experiment
carried out three times with similar results. (A) Immunolabelling of GRK2
in cytosol fraction; (B) immunolabelling of GRK2 in membrane fraction;
(C) the immunoreactivity was quantified by densitometric scanning from
bands; data were normalized by setting the control values to 100 for
cytosolic fraction and to 1 for membrane fraction. Data are meansF SEM
from three determinations. a, aV: control; b, bV: 10 AM NECA; c, cV: 50 AM
PD98059; d, dV: 10 AM NECA+ 50 AM PD98059; e, eV: 1 AM U0126; f, fV:
10 AM NECA+ 1 AM U0126.
M.L. Trincavelli et al. / Biochimica et Biophysica Acta 1591 (2002) 55–6260
Then we evaluated the role of A3 AR endocytosis in the
MAPK pathway activation. For several GPCRs, receptor
endocytosis play an important role in the assembly of
signalling proteins involved in MAPK activation, pointing
to a novel mechanism by which these receptors may be
linked to the mitogenic signalling machinery [12,13,32].
However, the requirement of receptor endocytosis for
MAPK activation does not seem to be a general property
of all GPCRs and all cellular systems [33,34]. The present
study showed that hypertonic sucrose, which has been
shown to reduce receptor internalization [23], did not abro-
gate NECA-induced ERK 1/2 activation, suggesting that A3
AR endocytosis is not required for immediate downstream
signalling via this pathway. Hypertonic sucrose proved to be
a viable strategy in our CHO cells, as it did not cause any
significant ERK 1/2 activation without agonist addition.
Consistent with this interpretation is the finding that ERK
1/2 activation occurred within 5 min, a time when agonist-
elicited receptor loss from the surface is just beginning. Our
results also suggested that ERK 1/2 phosphorylation may
be terminated by receptor internalization, since incubation
with sucrose induced a more sustained activation of the en-
zyme.
We also investigated the regulation of the A3 AR
function by the activated MAPK pathway. It has been
demonstrated that MAPK recruitment not only represents
a mitogenic signal but also a desensitizing signal for several
GPCRs [14]. The desensitization process is critical for
timing the duration of the cell response to a stimulus. Upon
signalling through GPCRs, the regulation of this process can
theoretically occur at any level of the interaction between
receptor, G protein and effector pathway. The role of GRKs
in receptor phosphorylation, uncoupling, and internalization
has been described elsewhere [10,11,35]. However, it is
possible that other signals contribute to the desensitization
process, as well. In this context, a recent paper describes the
important role of the MAPK cascade in the feedback
regulatory mechanism of several GPCRs [14,15]. To define
the direct role of the MAPK pathway in A3 AR regulation,
direct receptor phosphorylation was performed in the pres-
ence of the MAPKK inhibitors PD98059 and U0126. We
showed that agonist-induced A3 AR phosphorylation was
completely inhibited in the presence of PD98059 and was
only partially blocked by U0126, suggesting a regulatory
mechanism of A3 AR functioning by the MAPK cascade.
Furthermore, we showed that PD98059 and U0126, to a
different extent, affected agonist-induced A3 AR desensiti-
zation without affecting the ligand-receptor binding proper-
ties. In particular PD98058 completely impaired agonist-
mediated A3 AR desensitization, whereas U0126 only
caused a slow-down of desensitization kinetics, suggesting
that a feedback signal originating at the effector pathway
itself, in this case the MAPK pathway, may help to trigger
the desensitization mechanism. We also demonstrated that
agonist-promoted internalization of A3 AR was largely
blocked when MAPK activation was prevented by cell
preincubation with PD98059. On the contrary, U0126 cell
preincubation did not significantly affect A3 AR intracellu-
lar trafficking. As MAPK-mediated receptor control could
occur by a direct phosphorylation of A3 AR, as described,
e.g. for angiotensin II receptors [15], or by modulating the
activity of second messenger kinases, GRKs, which in turn
phosphorylate the receptor [16,17], we investigated the
effects of MAPKK inhibitors on GRK2 activation evaluating
the membrane translocation of these kinases. It has recently
been demonstrated that GRK2 mediates the phosphorylation
of Thr318 at the C-terminal tail of the A3 AR and control
receptor desensitization [25] and internalization [26]. The
results obtained demonstrated that PD98059 impaired the
agonist-mediated GRK2 translocation, whereas U0126 had
no significant effect towards this protein kinase. These
results confirmed the different specificities of these kinase
inhibitors in the control of the MAPK cascade [36]. It is
known that these inhibitors block the MAPK cascade in
cell-based assays by preventing the activation of MAPKK
and not by inhibiting MAPKK activity directly. In partic-
ular, PD98059 binds to MAPKK, preventing its activation
by an ‘‘upstream’’ protein kinase, such as Raf. PD98059 is
therefore not a protein kinase inhibitor, but a compound that
stops one protein kinase, Raf, from activating MAPKK.
U0126 inhibits the MAPK cascade by binding to specific
MAPKK1 and 2, involved in ERK 1/2 phosphorylation. In
this context it is not unlikely to speculate that A3 AR
regulation is controlled by the MAPK pathway in two
different phases: in a first acute phase the MAPK may help
to initiate receptor desensitization by a weak direct receptor
phosphorylation; in a second phase MAPKs modulate GRK
activity and control the complete receptor desensitization
and internalization. At now, few data are available regarding
the feedback MAPK regulation on GRK protein activity.
GRK2 activity, levels and subcellular localization are subject
to complex regulatory processes [37], including interaction
with Ghg subunits of G proteins, lipids, agonist-activated re-
ceptors, and phosphorylation by other kinases. GRK2 phos-
phorylation by protein kinase C (PKC) leads to an increased
kinase activity toward GPCR, probably due to an enhanced
kinase association to the plasma membrane [38,39]. On the
other hand, agonist stimulation of h2-adrenergic receptors,
which are coupled to Gas subunit of G protein, triggers the
rapid phosphorylation of GRK2 by Src which results in an
enhancement of GRK2 intrinsic activity [17]. A recent paper
reports that h2 adrenergic receptor activation promotes a
rapid association between GRK2 and MAPK leading to a
reduced GRK2 functionality [16]. In our experimental con-
ditions, MAPK seemed to be involved in a positive feedback
control of GRK2 activity. These effects may be explained on
the basis of the receptor coupling with different G proteins
subunits which, in turn, can stimulate different intracellular
signalling pathways and also promote different autoregula-
tory mechanisms. A better knowledge about the mechanisms
of GRK2 regulation, evoked by different GPCRs stimulation,
could shed light about the understanding of GPCR modu-
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lation and signalling. In conclusion, we showed that expo-
sure of A3 AR to the agonist induced a rapid, transient ERK
1/2 activation and that agonist-mediated receptor internal-
ization was not required for mitogenic signalling. We also
showed that an active MAPK pathway is essential for A3 AR
receptor phosphorylation, desensitization and internaliza-
tion. MAPK recruitment could thus be a key signalling
event, not only for the transduction of mitogenic signals to
the nucleus, but also for the initiation of homologous
desensitization of A3 AR. Moreover, the activation of
MAP kinase by A3 AR may also induce heterologous
desensitization processes through a crossed phosphorylation
of other receptor subtypes. Further studies will be required to
investigate this intracellular cross-talk. In this view, both
mitogenic and desensitizing signals emanating from the
MAPK cascade may contribute to the important adaptive
mechanisms that change the receptor function in patholog-
ical conditions.
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